Activaero appoints chief business officer

Christian Pangratz takes the role

Activaero, a German leader in controlled breathing inhalation technologies and therapeutics, has appointed Christian Pangratz as chief business officer.

Pangratz joins Activaero from Nektar Therapeutics, in San Francisco, US, where he recently served as executive director of business development. He brings to Activaero 20 years of life science experience.

Pangratz will join the Activaero management team and lead all business development, marketing and alliance management activities. He replaces Henrik Luessen, who has decided to focus on his own consultancy firm, but will continue to support Activaero’s business development team on a part-time basis.

You may also like

Finance

Vectura Group to buy Activaero for £108m

Will enable Vectura to build a therapeutic specialist in airways diseases
Drug Delivery

Shimadzu enhances dual ion source technology with compact LCMS-2050

The system combines high-speed analysis, energy efficiency, and advanced DUIS capability in a compact design
Training & Education

NSF celebrates 50 years of the Qualified Person, honouring 35 years of industry-leading training

NSF’s Claire Bettany shares how our QP Training Programme empowers future Qualified Persons with expert support, academic recognition, and practical success
Manufacturing

Titan develops bespoke calibration rig for ultra-low flow measurement

Company designs state-of-the-art system to support next-generation ultrasonic flowmeters
Finance

EMV Capital subsidiary Moirai acquires Destiny Pharma’s XF-73 antibiotic platform

The XF drug platform, designed to prevent bacterial resistance and combat Gram-positive infections such as MRSA, represents a high-impact addition to EMV’s life sciences portfolio
Regulatory

CHMP recommends Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria in EU

If approved, it would be the first targeted CSU therapy in the EU in more than a decade, supported by Phase III LIBERTY-CUPID data showing significant itch and hive reduction at 24 weeks
Finance

ScaleReady awards nearly $2m in G-Rex grants to advance cell and gene therapy manufacturing in California

The initiative supports leading academic GMP facilities in developing scalable, cost-effective platforms for CAR-T and other cell therapies, reinforcing California’s position as a global hub for CGT innovation
Subscribe now